indazoles has been researched along with Experimental Neoplasms in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (21.88) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 3 (9.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HY; Fu, LS; Li, MM; Liu, M; Liu, X; Liu, Z; Ma, YY; Sun, HT; Tian, XY; Wang, Y; Wang, YF; Zhang, PC | 1 |
| Zhang, X; Zhong, S | 1 |
| Bugide, S; Green, MR; Gupta, R; Wajapeyee, N | 1 |
| Benezra, R; Cook, PJ; de Leon, ES; Drilon, A; Kannan, R; Rosenblum, MK; Scaltriti, M; Thomas, R; Ventura, A | 1 |
| Alfranca, G; Cui, D; de la Fuente, JM; Pan, F; Song, J; Yang, Y; Yin, T; Yue, C; Zhang, C; Zhang, Q | 1 |
| Jung, KY; Kim, JE; Lee, CO; Lee, HK; Park, CH; Yoo, M | 1 |
| Gao, C; Gao, H; Liu, S; Liu, W; Xing, D | 1 |
| Cescon, DW; Chen, Y; Dmitrovsky, E; Kawakami, M; Kurie, JM; Liu, X; Mak, TW; Mino, B; Mustachio, LM; Rodriguez-Canales, J; Roszik, J; Silvester, J; Thu, KL; Villalobos, PA; Wistuba, II; Zheng, L | 1 |
| Chen, C; Ge, J; Hu, C; Hu, Z; Huang, T; Jiang, Z; Li, L; Liu, J; Liu, Q; Liu, X; Ren, T; Wang, A; Wang, B; Wang, J; Wang, L; Wang, W; Wu, H; Xia, R; Zhang, Y | 1 |
| Berglund, UW; Blackhall, F; Chester, CPE; Dive, C; Frese, KK; Gorgoulis, VG; Gulati, S; Helleday, T; Kalderen, C; Khandelwal, G; Lallo, A; Miller, C; Pateras, IS; Pham, TM; Schenk, MW | 1 |
| Gao, X; Tan, S; Wang, L; Wang, Q; Wu, G; Wu, J; Zou, C | 1 |
| Bejot, R; Bhakoo, KK; Goggi, JL; Moonshi, SS | 1 |
| Berger, W; Heffeter, P; Jungwith, U; Keppler, BK; Konstantinova, T; Körner, W; Kowol, CR; Mitina, N; Riabtseva, A; Senkiv, Y; Stoika, R; Yanchuk, I; Zaichenko, A | 1 |
| DiGiammarino, EL; Donawho, CK; Gao, W; Hopkins, TA; Johnson, EF; Maag, D; Olson, AM; Osterling, DJ; Panchal, SC; Rodriguez, LE; Shi, Y; Solomon, LR; Stolarik, DF; Wilsbacher, JL | 1 |
| Choi, HG; Choi, JY; Jeong, JH; Kim, J; Kim, JO; Kim, JR; Kim, SY; Ku, SK; Ramasamy, T; Yong, CS; Youn, YS | 1 |
| Ai, J; Dai, Y; Duan, W; Fan, J; Gao, Y; Geng, M; Luo, C; Meng, F; Wang, X; Wang, Y; Yan, W; Yang, X; Zhao, B | 1 |
| Amundson, K; Bender, SL; Chen, JH; Grazzini, ML; Hallin, ME; Hu-Lowe, DD; Kania, RS; McTigue, MA; Murray, BW; O'Connor, P; Rewolinski, DA; Shalinsky, DR; Wickman, GR; Wu, EY; Yamazaki, S; Zou, HY | 1 |
| Bronson, RT; Cheng, KA; Curtin, NJ; D'Andrea, AD; Johnson, N; Li, D; Li, YC; Moreau, LA; Newell, DR; Rodig, SJ; Shapiro, GI; Thomas, HD; Unitt, C; Walton, ZE; Wong, KK | 1 |
| Belmont, LD; Belvin, M; Berry, L; Friedman, LS; Guan, J; Koeppen, H; Lee, LB; Prior, WW; Sampath, D; Wallin, JJ | 1 |
| Cheng, CY; Liu, T; Liu, Y; Mruk, DD; Shao, J; Silvestrini, B; Wang, B; Xia, W; Xie, QR; Yang, J; Zhang, T | 1 |
| Konovalova, NP | 1 |
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Rotin, D; Tannock, IF | 1 |
| Silvestrini, B | 1 |
| Cioli, V; De Martino, C; Hahn, GM; Silvestrini, B | 1 |
| Caputo, A; De Martino, C; Floridi, A; Marcante, ML; Paggi, MG; Silvestrini, B | 1 |
| Caputo, A | 1 |
| Chen, LK; Hall, ES; Hall, IH; Wong, OT | 1 |
| Barcellona, PS; Heywood, R; Patton, DS | 1 |
| Goddard, PM; Harrap, KR; Jones, M; Pollard, LA; Valenti, MR | 1 |
| Adwankar, MK; Chitnis, MP | 1 |
| Alfieri, AA; Kim, JH; Kim, SH; Young, CW | 1 |
32 other study(ies) available for indazoles and Experimental Neoplasms
| Article | Year |
|---|---|
AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; PC12 Cells; Pheochromocytoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2020 |
EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Topics: Animals; Benzopyrans; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Chemokine CXCL10; Chemokines; Decitabine; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Indazoles; Indoles; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Phenols; Pyridones; Sulfones; Triazoles | 2021 |
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
Topics: Animals; Benzamides; Brevican; CRISPR-Cas Systems; Drug Screening Assays, Antitumor; Feasibility Studies; Female; Gene Editing; Glioma; Humans; Indazoles; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Oncogene Fusion; Primary Cell Culture; Receptor, trkA | 2017 |
Mitochondria-targeting near-infrared light-triggered thermosensitive liposomes for localized photothermal and photodynamic ablation of tumors combined with chemotherapy.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Indazoles; Infrared Rays; Liposomes; Mice; Mice, Inbred BALB C; Mitochondria; Neoplasms, Experimental; Photochemotherapy; Photosensitizing Agents; Xenograft Model Antitumor Assays | 2017 |
Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Nuclear Proteins; Structure-Activity Relationship; Transcription Factors | 2018 |
Bindarit Attenuates Pain and Cancer-Related Inflammation by Influencing Myeloid Cells in a Model of Bone Cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carcinogenesis; Cell Line, Tumor; Chemokine CCL2; Disease Models, Animal; Humans; I-kappa B Kinase; Indazoles; Inflammation; Male; Mice; Mice, Nude; Myeloid Cells; Neoplasms, Experimental; Propionates; Signal Transduction; Tumor Burden | 2018 |
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Centrosome; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Mice; Neoplasms, Experimental; Polyploidy; Protein Serine-Threonine Kinases | 2018 |
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants includi
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Mutation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship | 2018 |
Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred Strains; Mice, SCID; Neoplasms, Experimental; Neoplastic Cells, Circulating; Small Cell Lung Carcinoma; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured | 2019 |
Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer.
Topics: Animals; Delayed-Action Preparations; Doxorubicin; Drug Resistance, Neoplasm; Humans; Hydrazines; Hydrogen-Ion Concentration; Indazoles; MCF-7 Cells; Mice; Nanoparticles; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2019 |
Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Imidazoles; Indazoles; Isotope Labeling; Mice; Neoplasms, Experimental; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diffusion; Drug Compounding; Drug Design; Drug Evaluation, Preclinical; Humans; Indazoles; Nanocapsules; Neoplasms, Experimental; Organometallic Compounds; Ruthenium Compounds; Treatment Outcome | 2014 |
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Tolerance; Humans; Indazoles; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2015 |
PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Topics: Animals; Axitinib; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Imidazoles; Indazoles; Lipid Bilayers; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Pentacyclic Triterpenes; Porosity; Silicon Dioxide; Triterpenes | 2016 |
Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Female; Humans; Indazoles; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Receptors, Fibroblast Growth Factor; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2016 |
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Blotting, Western; Cell Line, Tumor; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Immunoprecipitation; Indazoles; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Topics: Animals; Benzimidazoles; Blotting, Western; BRCA1 Protein; Breast Neoplasms; Carrier Proteins; CDC2 Protein Kinase; Cell Death; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Nuclear Proteins; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; RNA-Binding Proteins | 2011 |
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Survival; Docetaxel; Drug Synergism; Female; Humans; Indazoles; Mice; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides; Taxoids | 2012 |
Male contraceptive Adjudin is a potential anti-cancer drug.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Contraceptive Agents, Male; Humans; Hydrazines; Indazoles; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental | 2013 |
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Indazoles; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Mitomycin; Neoplasm Metastasis; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
The effect of the drug lonidamine on Chinese hamster ovary cells in vitro and on experimental tumors.
Topics: Animals; Antispermatogenic Agents; Cell Line; Cell Survival; Combined Modality Therapy; Cricetinae; Cricetulus; Doxorubicin; Hydrogen-Ion Concentration; Indazoles; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Oxygen; Pyrazoles | 1984 |
Basic and applied research in the study of indazole carboxylic acids.
Topics: Animals; Antispermatogenic Agents; Behavior, Animal; Dose-Response Relationship, Drug; Female; Fetal Death; Haplorhini; Humans; Indazoles; Lethal Dose 50; Male; Neoplasms, Experimental; Pregnancy; Pyrazoles; Rats; Spermatogenesis; Structure-Activity Relationship | 1981 |
Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Division; Cell Survival; Cricetinae; Cricetulus; Female; Hot Temperature; Humans; Indazoles; Male; Mice; Microscopy, Electron; Mitochondria; Neoplasms, Experimental; Pyrazoles | 1983 |
Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.
Topics: Animals; Energy Metabolism; Glycolysis; Hexokinase; Indazoles; Lactates; Mice; Mitochondria; Neoplasms, Experimental; Oxygen Consumption; Pyrazoles | 1981 |
Preliminary results in some tumor systems with indazolecarboxylic acids.
Topics: Animals; Body Weight; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Germ Cells; Glycolysis; Indazoles; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Time Factors | 1981 |
The cytotoxicity of N-substituted indazolones in murine and human tumor cells.
Topics: Animals; Antineoplastic Agents; Biological Availability; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indazoles; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Nucleic Acid Denaturation; Tumor Cells, Cultured | 1993 |
Carcinogenicity assessment of lonidamine by dietary administration to Sprague-Dawley rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Epididymis; Female; Indazoles; Male; Mammary Glands, Animal; Neoplasms, Experimental; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Testis | 1992 |
The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
Topics: Animals; Cisplatin; Drug Interactions; Drug Therapy, Combination; Granisetron; Indazoles; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Plasmacytoma; Pyrazoles; Serotonin Antagonists | 1990 |
Modification of tumor cell sensitivity to antineoplastic agents lonidamine and bouvardin (NSC 259968) at elevated temperatures.
Topics: Animals; Antineoplastic Agents; DNA; Drug Resistance; Hyperthermia, Induced; Indazoles; Leukemia P388; Mice; Neoplasms, Experimental; Peptides, Cyclic; Pyrazoles; Sarcoma 180; Thymidine; Tritium | 1986 |
Potentiation of radiation effects on two murine tumors by lonidamine.
Topics: Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Energy Metabolism; Indazoles; Metabolic Clearance Rate; Mice; Neoplasms, Experimental; Pyrazoles; Radiation-Sensitizing Agents; Skin; Time Factors | 1986 |